Fibrinolytic Therapy in Thrombosis of Mechanical Valves: Outcomes and Complications.

IF 0.5 Q4 CARDIAC & CARDIOVASCULAR SYSTEMS
Ali Nasri Nasrabadi, Fahimeh Yarahmadi, Afshin Amirpour, Reyhaneh Zavar, Mojtaba Akbari
{"title":"Fibrinolytic Therapy in Thrombosis of Mechanical Valves: Outcomes and Complications.","authors":"Ali Nasri Nasrabadi, Fahimeh Yarahmadi, Afshin Amirpour, Reyhaneh Zavar, Mojtaba Akbari","doi":"10.48305/arya.2023.26569.2804","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Valvular heart disease presents a significant and escalating global health challenge. Prosthetic valve thrombosis (PVT) following surgical valve replacement is a primary cause of valve failure. The aim of this study was to ascertain the outcomes and complications of fibrinolytic therapy in patients diagnosed with PVT.</p><p><strong>Method: </strong>This cross-sectional study enrolled 81 patients diagnosed with PVT who underwent fibrinolytic therapy between 2008 and 2018. Streptokinase was administered to 87.6% of patients, while 12.4% received reteplase. All demographic and clinical data were gathered from the patients' medical records. The incidence of successful recovery and complications were assessed.</p><p><strong>Results: </strong>The records of 81 patients (43.2% male, mean age: 51.6 ± 13.9 years) were examined. The findings revealed that 59% and 35% of the patients had mitral and aortic PVT, respectively. While 12% of the patients experienced drug complications, 90% achieved successful recovery. Stroke and severe hemorrhage were complications frequently reported by the patients treated with streptokinase (8% and 4% respectively). The patients treated with reteplase demonstrated a 100% recovery rate. Conversely, 89% of the patients treated with streptokinase achieved successful recovery, and 7% of the patients experienced a partial recovery.</p><p><strong>Conclusion: </strong>Fibrinolytic agents can serve as an effective treatment with an excellent success rate for managing PVT in patients post-surgical valve replacement.</p>","PeriodicalId":46477,"journal":{"name":"ARYA Atherosclerosis","volume":"19 5","pages":"18-24"},"PeriodicalIF":0.5000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179002/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ARYA Atherosclerosis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.48305/arya.2023.26569.2804","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Valvular heart disease presents a significant and escalating global health challenge. Prosthetic valve thrombosis (PVT) following surgical valve replacement is a primary cause of valve failure. The aim of this study was to ascertain the outcomes and complications of fibrinolytic therapy in patients diagnosed with PVT.

Method: This cross-sectional study enrolled 81 patients diagnosed with PVT who underwent fibrinolytic therapy between 2008 and 2018. Streptokinase was administered to 87.6% of patients, while 12.4% received reteplase. All demographic and clinical data were gathered from the patients' medical records. The incidence of successful recovery and complications were assessed.

Results: The records of 81 patients (43.2% male, mean age: 51.6 ± 13.9 years) were examined. The findings revealed that 59% and 35% of the patients had mitral and aortic PVT, respectively. While 12% of the patients experienced drug complications, 90% achieved successful recovery. Stroke and severe hemorrhage were complications frequently reported by the patients treated with streptokinase (8% and 4% respectively). The patients treated with reteplase demonstrated a 100% recovery rate. Conversely, 89% of the patients treated with streptokinase achieved successful recovery, and 7% of the patients experienced a partial recovery.

Conclusion: Fibrinolytic agents can serve as an effective treatment with an excellent success rate for managing PVT in patients post-surgical valve replacement.

机械瓣膜血栓形成时的纤维蛋白溶解疗法:结果与并发症
引言瓣膜性心脏病是全球健康面临的一个重大挑战,而且这一挑战还在不断升级。手术瓣膜置换术后人工瓣膜血栓形成(PVT)是瓣膜功能衰竭的主要原因。本研究旨在确定纤溶疗法在确诊为 PVT 患者中的疗效和并发症:这项横断面研究招募了81名确诊为PVT的患者,他们在2008年至2018年间接受了纤维蛋白溶解疗法。87.6%的患者接受了链激酶治疗,12.4%的患者接受了再普酶治疗。所有人口统计学和临床数据均来自患者的医疗记录。对成功康复的发生率和并发症进行了评估:对 81 名患者(43.2% 为男性,平均年龄:51.6 ± 13.9 岁)的病历进行了检查。结果显示,分别有 59% 和 35% 的患者患有二尖瓣和主动脉瓣下血栓。虽然 12% 的患者出现了药物并发症,但 90% 的患者成功康复。中风和严重出血是接受链激酶治疗的患者经常报告的并发症(分别为8%和4%)。接受雷替普酶治疗的患者的康复率为 100%。相反,89%接受链激酶治疗的患者成功康复,7%的患者部分康复:结论:纤溶药物可作为一种有效的治疗方法,在控制手术瓣膜置换术后患者的静脉血栓形成方面具有极高的成功率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ARYA Atherosclerosis
ARYA Atherosclerosis CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
1.00
自引率
0.00%
发文量
0
审稿时长
18 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信